The Home of the Life Sciences Industry

Explore Latest News

Lundbeck Acquires Prexton Therapeutics

Lunbeck is acquiring Prexton Therapeutics BV, a 2012 spinout from Merck KgaA, and its Phase II treatment for Parkinson’s disease.

Arbor Biotechnologies Comes Out of Stealth Mode

Arbor Biotechnologies came out of stealth mode yesterday with a $15.6 million Series A financing round.


Post jobs on BioSpace and start building your talent pipeline today. Click the button to access our easy eCommerce site, which lets you purchase and post jobs in just a few clicks.